{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-151812","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.937449+00:00","generated_at":"2026-06-25T15:39:23.367285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IO Biotech Q1 2022 net loss $17.2M; cash $187.9M; Phase 2 trial initiated","bullets":["Net loss of $17.2M for Q1 2022 vs $3.7M in Q1 2021; R&D expenses $10.3M (up $7.5M).","Cash and equivalents $187.9M at March 31, 2022, down from $211.5M at Dec 31, 2021; runway to mid-2024.","Initiated Phase 2 trial (IOB-022/KN-D38) of IO102-IO103 with pembrolizumab in first-line treatment.","Updated Phase 1/2 data for IO102-IO103 + nivolumab in metastatic melanoma showed 73% 3-year survival probability.","Phase 3 trial (IOB-013/KN-D18) with Merck ongoing; guidance on interim readout timing expected mid-2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-151812","json":"https://secwatch.observer/filing/0001193125-22-151812.json","markdown":"https://secwatch.observer/filing/0001193125-22-151812.md","text":"https://secwatch.observer/filing/0001193125-22-151812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522151812/0001193125-22-151812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522151812/d334702d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:39:23.367285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}